If you are a big pharmaceutical company, spending millions of dollars to manage your intellectual property every year, you will want to find the best lawyers to advise you on prosecution and litigation matters. But as Susanne Sivborg, vice-president of global intellectual property at AstraZeneca, tells Stéphanie Bodoni, the most experienced lawyers are no good if they do not respond to her company's needs
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The model covers court-guided settlements, submissions-led determination of infringement and validity issues, and provides leeway for the court to determine a FRAND rate during negotiations